RET inhibition in RET aberrant cancers

Bookmark and Share
Published: 10 Jul 2019
Views: 887
Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, USA

Dr Vivek Subbiah speaks to ecancer at the WIN 2019 Symposium in Paris about RET inhibition in RET aberrant cancers.

He explains that RET is an oncogenic driver seen in multiple cancers, most commonly lung cancers.

Dr Subbiah discusses various RET inhibitors with an important one being including BLU-667 which, following study, has been granted two US breakthrough designations.